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Introduction: The 2008 National Mastectomy and Breast Reconstruction Audit demonstrated marked
variation in the practice and outcomes of breast reconstruction in the UK. To standardise practice and
improve outcomes for patients, the British professional associations developed best-practice guidelines
with specific guidance for newer mesh-assisted implant-based techniques. We explored the degree of
uptake of best-practice guidelines within units performing implant-based reconstruction (IBBR) as the
first phase of the implant Breast Reconstruction Evaluation (iBRA) study.
Methods: A questionnaire developed by the iBRA Steering Group was completed by trainee and
consultant leads at breast and plastic surgical units across the UK. Simple summary statistics were
calculated for each survey item to assess compliance with current best-practice guidelines.
Results: 81 units from 79 NHS Trusts completed the questionnaire. Marked variation was observed in
adherence to guidelines, especially those relating to clinical governance and infection prevention stra-
tegies. Less than half (n ¼ 28, 47%) of units obtained local clinical governance board approval prior to
offering new mesh-based techniques and prospective audit of the clinical, cosmetic and patient-reported
outcomes of surgery was infrequent. Most units screened for methicillin-resistant staphylococcus aureus
prior to surgery but fewer than 1 in 3 screened for methicillin-sensitive strains. Laminar-flow theatres
(recommended for IBBR) were not widely-available with less than 1 in 5 units having regular access. Peri-
operative antibiotics were widely-used, but the type and duration were highly-variable.esearch, Population Health Sciences, Bristol Medical School, University of Bristol, 39 Whatley Road, Clifton, Bristol, BS8
tter).
Reconstruction Research Collaborative are PUBMED citable collaborators in this study and are listed at the end of the
Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
S. Mylvaganam et al. / European Journal of Surgical Oncology 44 (2018) 708e716 709Conclusions: The iBRA national practice questionnaire has demonstrated variation in reported practice
and adherence to IBBR guidelines. High-quality evidence is urgently required to inform best practice.
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
National Institute for Health and Care Excellence (NICE) guide-
lines recommending the routine offer of immediate breast recon-
struction to women requiring mastectomy for breast cancer were
introduced in 2002 [1], but in 2008, the National Mastectomy and
Breast Reconstruction Audit (NMBRA) demonstrated marked
variation in the availability and outcomes of breast reconstruction
in the UK [2e5].
There was a need to standardise practice and to improve out-
comes for patients. In response to the NMBRA findings. The British
breast and plastic surgical professional associations (Association of
Breast Surgery, ABS and British Association of Plastic Reconstruc-
tive and Aesthetic Surgeons, BAPRAS) subsequently developed
‘Oncoplastic Breast Reconstruction: Guidelines for Best Practice’ [6].
The guidelines were based on consensus opinion informed by best
published evidence. They covered all types of breast reconstruction
and included recommendations for each stage of the clinical
pathway from diagnosis to post-operative follow-up. The guide-
lines included 25 quality criteria (QC) and were proposed as a
standardized ‘framework that should be used to assess current
practice and deliver high quality care’ [7].
Implant-based breast reconstruction (IBBR) is the most
commonly performed reconstructive procedure in the UK [8] and a
rapidly-evolving technique. Traditionally a two-stage procedure,
the introduction of biological (e.g. acellular dermal matrix, ADM)
and synthetic (e.g. titanium-coated polypropylene) meshes for
lower pole coverage offered patients the possibility of single-stage,
direct-to-implant reconstruction without the need for painful and
time-consuming expansions and a second operation [9]. The more
natural-looking ptotic breasts created using mesh also resulted in
increasing numbers of women being offered the procedure and led
to a decline in more traditional latissimus dorsi flap-based recon-
struction [8,10].
Despite the proposed benefits of mesh, concerns were raised
that complication rates in mesh-assisted IBBR were unacceptably
high [11e13]. The ABS and BAPRAS therefore published supple-
mental guidance on mesh-assisted implant reconstruction [14] to
support surgeons offering the technique. The guidelines included
recommendations for patient selection and unit and organization
criteria for centres wishing to be commissioned to perform mesh-
assisted reconstruction. Evidence to support the recommenda-
tions was acknowledged to be lacking and in the absence of evi-
dence, the guidelines were based largely on expert opinion [14].
The need for outcome data was highlighted and one of the main
aims of the guidance was to identify clinical standards and quality
indicators against which centres offering the technique could audit
their results [14]. Key recommendations for the practice of IBBR
from both the Oncoplastic Breast Surgery Guidelines for Best
Practice [6] and supplemental ADM guidelines [14] are summarized
in Table 1.
The practice of IBBR has continued to develop and over 85% of
immediate breast reconstructions in the UK are now implant-based
[8]. Despite the widespread adoption of mesh-assisted reconstruc-
tion into routine clinical practice, robust evidence for the safety and
effectiveness of the techniques remains elusive [15,16]. Various
biological and synthetic meshes have been introduced withsignificant variations in cost and in the absence of evidence of
effectiveness, product selection is dependent on surgeonpreference.
High-quality research is therefore required to establish best
practice in IBBR [15,16] and the iBRA (implant Breast Reconstruc-
tion evAluation) study is a national trainee-led multicentre cohort
study which aims to inform the feasibility, design and conduct of a
randomized clinical trial in IBBR [17]. The first phase of iBRA was a
national practice questionnaire (NPQ) where we aimed to explore
current practice [10] and the degree to which units performing
IBBR in the UK adhered to existing best practice guidelines to
inform the design of a future trial.
Methods
The national practice questionnaire (NPQ, Appendix 1) was
developed in February 2014 by members of the iBRA steering group
based on a comprehensive review of the literature [15], current pro-
fessional guidelines [6,14] and clinical expertise. It included unit de-
mographic data and items assessing adherence to quality criteria and
practice recommendationsmade in the joint ABS/BAPRAS oncoplastic
breast reconstruction [6] andADMreconstruction guidelines [14]with
particular focus on clinical governance issues such as audit and
infection reduction strategies to inform future trial design. The ques-
tionnaire was piloted with surgeons at two hospitals to ensure face
and content validity prior to distributing the questionnaire nationally.
All breast and plastic surgical units performing mastectomy
with or without immediate breast reconstruction in the UK were
eligible for inclusion. Trainees were invited to participate via the
Mammary Fold breast trainees' group and the Reconstructive Sur-
gery Trials Network (RSTN). ABS and BAPRAS endorsed the study
and encouraged units to participate. Each participating trainee was
required to identify a consultant lead in their unit. The trainee
completed the questionnaire with this consultant ensuring that
responses reflected the practice of the unit as a whole, rather than
those of an individual surgeon.
Data were collected and managed using REDCap electronic data
capture tools hosted at University of Edinburgh [18].
Analysis
Descriptive summary statistics were calculated for each survey
item to evaluate adherence to each guideline or recommendation.
Categorical data was summarized by counts and percentages.
Continuous data was summarized by median, interquartile range
(IQR) and range. No data imputation methods were used for items
with no response and when a unit did not complete a specific
section of the questionnaire, it was assumed that the unit did not
offer that approach. Statistical Analysis Software (SAS® 9.1.3; SAS
Institute Inc., Cary, NC, USA) was used for all analyses. Free text
responses were collated and analysed using content analysis.
Results
Participation
81 responses were received from 79 NHS Trusts. Two trusts had
independent responses from the breast and plastic surgical units.
Table 1
Summary of current best practice guidelines for implant-based breast reconstruction.
Guideline Source
Organizational criteria for units wishing to be commissioned for ADM assisted reconstruction
 Approval from New Procedure Policy/Clinical Governance Board specific to each hospital Trust Joint ABS/BAPRAS ADM
guidelines Patient awareness that they are being offered a relatively new procedure
 Clear pathway and service arrangement to manage drains up to 3 weeks post-operatively
 Ongoing audit of all complications arising from all breast reconstruction operations
 Agreement to participate in future national clinical ADM audit and submit all cases
Unit criteria for units wishing to be commissioned for ADM assisted reconstruction
 Experience breast reconstruction team Joint ABS/BAPRAS ADM
guidelines Prospective record and photographic collection
 Guidelines to staff on post-operative management with agreed protocols of care (drains, follow-up, antibiotics)
 All cases should be audited prospectively
Participation in research and audit
 Eligible patients are invited to take part in local and national clinical trials and audits of OPBS OPBR-guidelines for best
practice Target: Screening for eligibility for clinical trials and national audits occurs in 100% of OPBS patients (QC22)
Target standards from the National Mastectomy and Breast Reconstruction Audit (NMBRA)
Pre-operative guidelines and proposed quality standards
Medical photography OPBR - guidelines for best
practice Medical photography (pre-and post-operative) is part of the clinical record
 Target: Medical photography is offered in 100% of BR patients (QC4)
Information provision OPBR-guidelines for best
practice Patients receive information in a format and level of detail that meets their individual needs. The letter to the GP
summarises the information provided and is copied to the patient
 Target: Written information about the risks and benefits of breast reconstruction is provided to 90% of mastectomy
patients
Peri-operative guidelines and recommendations to reduce the risk of infection
Preoperative MRSA and MSSA screening OPBR-guidelines for best
practice and NICE Surgical Site
Infection Clinical Guideline
2008
 Patients are MRSA (þMSSA in implant cases) screened prior to admission and have topical suppression where positive
in accordance with national/local policy
 Target: MRSA screening occurs in 100% of patients prior to admission (QC7)
Peri-operative antibiotic use
 Patients undergoing implant-based reconstruction are given a single intravenous dose of appropriate antibiotic(s) on
induction
 The antibiotic spectrum of prophylaxis should cover both Gram positive and Gram negative bacteria, particularly the
most common cause of post-operative infection, Staphylococcus aureus
 Regimens may differ between hospitals and local prescribing policies but flucloxacillin and gentamicin or cefuroxime
are appropriate options. In truly penicillin allergic patients, clindamycin and gentamicin or vancomycin/
 teicoplanin and gentamicin may be considered. The latter regimen should be used for patients known to be colonised
with MRSA
 Target: All patients undergoing implant-based reconstruction receive intravenous antibiotics on induction (QC11)
Use of laminar flow theatres
 Ultra Clean Ventilation (UCV, ‘laminar flow’) is recommended in OPBS where such facilities are available:
 If unavailable, the number of personnel in theatre and ‘theatre traffic’ should be actively reduced to a minimum to
reduce turbulent air flow and minimize the bacterial load in the theatre air.
 A policy of minimal movement of personnel within the operating theatre is a recommended principle whatever the
theatre ventilation system
Skin preparation
 2% chlorhexidine with 70% isopropyl alcohol with tint provides the best skin decontamination for the most prolonged
period. It should be applied to the whole area to be decontaminated, but sparingly to avoid pooling.
 Povidone iodine or isopropyl alcohol are less effective alternatives.
Implant cavity irrigation
 The implant cavity may be washed out to remove any necrotic material
Minimal implant handling and glove change
 The implant should be opened just before use to reduce contamination from airborne bacteria.
 The surgeon should use a ‘minimal or no touch’ technique where possible to reduce the risks of contamination of the
implant. Care should be taken when changing gloves. A safe option is to leave existing gloves on and double glove just
before handling the implant or to wear two pairs of gloves from the start of the procedure, removing the outer gloves
before handling the implant.
Post-operative guidelines and proposed quality standards
Antibiotic use for suspected post-operative infection Joint ABS/BAPRAS ADM
guidelines Infection <10% of patients require antibiotics within 3 months of their surgery for suspected infection
Assessment of clinical outcomes OPBR-guidelines for best
practice Implant loss, unplanned return to theatre, unplanned readmission (QC15, QC16, QC17) at 3 months are assessed and
audited
 Post-operative complications, return to theatre and length of stay are documented in departmental BR database
 Target: There is a regular audit and discussion of all patients with post-operative complications (QC18)
Assessment of patient reported outcomes OPBR-guidelines for best
practicePatients' satisfaction with BR outcome is measured using standardized assessment tools:
 Satisfaction with information at 3 months (QC19); Target: Satisfaction with information provision is reported by 80%
of patients at 3 months
 Satisfaction with appearance clothed at 18 months (QC20); Target: At 18 months, over 90% of BR patients report
satisfaction with their appearance clothed (QC20)
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practices despite stemming from the same trust. 67 of 144 (47%)
breast units and 14 of 53 (26%) plastic units in the UK participated.
Responses were received from both high and low volume centres
with participating units performing a median of 35 IBBR per year
(range 0e230). Of the participating breast units, 23/67 (34%) had
on-site plastic surgical services with access to free-flap recon-
struction. Demographics of participating units are summarized in
Table 2.
Compliance with clinical governance guidelines for mesh-assisted
procedures
79/81 (98%) units provided details of the types of IBBR per-
formed. Of these 60/79 (76%) performed biological mesh (BM)
assisted reconstruction and 24/79 (30%) offered patients IBBR with
synthetic mesh (SM).
Compliance with recommendations for the introduction of
mesh-assisted IBBR was low. Only 28/60 (47%) units offering BM
and 4/24 (17%) units offering SM had sought approval from a ‘New
Techniques and Devices’ or other appropriate clinical governance
committee prior to introducing the technique. Formal written unit
protocols regarding themanagement of patients undergoing mesh-
assisted reconstruction were uncommon with only a third (n ¼ 21,
35%) of units using BM and less than 20% (4/24, 17%) of those using
SM reporting having agreed policies for the management of drains
and antibiotics in this group. Specific written information for pa-
tients undergoing mesh-assisted reconstruction was similarly
lacking with only a third (23/60, 38%) of units offering BM and aTable 2
Demographics of participating units.
Unit characteristic
Types of breast reconstruction offered
Implant-based reconstruction
Pedicled flaps
Latissimus dorsi
Pedicled TRAM
Free flaps
DIEP
Other autologous (e.g SGAP, IGAP, TUG, SIEA)
Therapeutic mammoplasty
Revisional surgery
Number of staff performing breast and reconstructive surgery
Breast surgery
Number of consultant surgeons with an interest in breast surgery (FTE, media
Number of consultant breast surgeons who perform reconstructive surgery (F
Plastic surgery
Number of consultant plastic surgeons with an interest in breast surgery (FTE
Number of consultant plastic surgeons who perform reconstructive surgery (F
Number of immediate implant-based breast reconstructions performed pe
Percentage of immediate breast reconstructions that are implant-based (m
Approaches to implant-based reconstruction offered
Standard 2 stage submuscular placement
Reduction pattern with dermal sling
Acellular dermal matrix assisted reconstruction
Other non-dermal biological-assisted reconstruction
TiLOOP assisted reconstruction
Other synthetic assisted reconstruction
DIEP e deep inferior epigastric perforator; FTE e full time equivalent; IQR e intquarter (4/24) of units offering SM reporting that this was available
locally.
Routine prospective audit of the clinical, cosmetic and patient-
reported outcomes of reconstructive surgery is a key recommen-
dation, but compliance was also low. Only half of units (31/60 BM
units and 12/24 SM units) prospectively audited the short and long-
term clinical outcomes of mesh-assisted IBBR with a further
25e30% (15/60 (24%) BM units and 7/24 (29%) SM units) reporting
that audit was undertaken retrospectively. Cosmetic outcomes
were audited by approximately half of units (33/60, 55% BM and 10/
24, 42% SM units) but less than a third assessed patient-reported
outcomes (Table 3).
Procedure coding for reimbursement is important for the
integrity of national data sets and units were asked how mesh-
assisted IBBR was coded locally. Two-thirds of respondents pro-
vided either an OPCS (Office of Population Censuses and Surveys) or
a HRG (Healthcare Resource Group) code and the responses varied.
Commonly-reported OPCS codes were of ‘skin-sparing mastec-
tomy’ (B27.6) with ‘insertion of prosthesis for breast’ (B30.1) and
‘reconstruction of the breast, Other specified’ (B30.8). The generic
HRG code JA16Z ‘Mastectomy and breast reconstruction’ was often
used but between 20% (12/60 BM units) and 30% (7/24 SM units)
units offering mesh-assisted IBBR reported being unsure how the
procedure was coded (Table 3).
Compliance with strategies to reduce infection
80/81 (99%) units responded to items relating to compliance
with best-practice for infection prevention. Most units (66/80, 83%)N ¼ 79
79 (100)
76 (96)
31 (39)
34 (43)
24 (30)
75 (95)
77 (97)
n, IQR, range) 3.0
(2.0e3.8)
(0.0e7.0)
TE, median, IQR, range) 2.5
(2.0e3.0)
(0.0e7.0)
, median, IQR, range) 1.0
(0e3.0)
(0.0e21.0)
TE, median, IQR, range) 2.0
(1.0e3.0)
(0.0e10.0)
r year (median, IQR, range) 35 (20e50)
(0e230)
edian, IQR, range) 70.0 (50.0e80.0)
(0.0e100.0)
60 (75.9)
66 (83.5)
59 (74.7)
19 (24.1)
19 (24.1)
8 (10.1)
erquartile range; TRAM e transverse rectus abdominis myocutaenous flap.
Table 3
Adherence to clinical governance guidelines for implant-based breast reconstruction.
ADM (n ¼ 60, %) TiLOOP (n ¼ 24, %)
Approval from the New Techniques and Devices Committee/Clinical Governance Board prior to introducing technique
Yes 28 (47) 4 (17)
No 14 (23) 13 (54)
Unsure 18 (30) 5 (21)
Missing 0 (0) 2 (8)
Formal written unit protocol or agreed guidelines for the management of patients undergoing mesh assisted (e.g regarding antibiotic
prophylaxis and drain management)?
Yes 21 (35) 4 (17)
No 34 (57) 15 (63)
Unsure 5 (8) 2 (8)
Missing 0 (0) 3 (13)
Availability of specific written information available to women considering mesh assisted reconstruction
Yes 23 (38) 6 (25)
No 30 (50) 15 (63)
Unsure 6 (10) 1 (4)
Missing 1 (2) 2 (8)
Audit of outcomes
Short term complications (<3 months)
Prospectively 31 (52) 12 (50)
Retrospectively 15 (25) 7 (29)
Not audited 11 (18) 3 (13)
No response/missing 3 (5) 2 (8)
Long term complications (>3 months)
Prospectively 24 (40) 9 (38)
Retrospectively 15 (25) 8 (33)
Not audited 17 (28) 4 (17)
No response/missing 4 (7) 3 (13)
Cosmetic outcomes using pre and post-operative photographs
Prospectively 24 (40) 6 (25)
Retrospectively 9 (15) 4 (17)
Not audited 24 (40) 10 (42)
No response/missing 3 (5) 4 (17)
Patient reported outcomes
Prospectively 6 (10) 2 (8)
Retrospectively 8 (13) 6 (25)
Not audited 44 (73) 14 (58)
No response/missing 2 (3) 2 (8)
Procedure coding
OPCS Codes
B27.4 Total mastectomy NEC 1 0
B27.6 Skin-sparing mastectomy 9 2
B29 Reconstruction of breast 2 2
B29.8 Reconstruction of breast, Other specified 13 6
B30 Prosthesis for breast 1 2
B30.1 Insertion of prosthesis for breast 10 5
B30.8 Prosthesis for breast, Other specified 1 0
S37.4 Xenograft of skin NEC 1 0
Y27.3 Xenograft to organ NOC 2 0
Y27.6 Prosthetic graft NOC 0 1
Y36.2 Introduction of therapeutic implant into organ 1 0
B3014/B3013 Mastectomy and immediate 1 0
reconstruction using a fixed prosthesis (B3013)
expandable prosthesis (B3014)
HRG codes
JA16Z Mastectomy and breast reconstruction 7 1
Unsure/no specific code 12 7
Missing 20 8
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(MRSA) prior to implant surgery but less than a third (25/80, 31%)
screened for the methicillin-sensitive strain, MSSA. Use of ultra
clean ventilation is recommended for implant cases but just 1 in 5
centres (15/80, 19%) routinely had access to laminar flow theatres.
Skin preparation with 2% chlorhexidine with 70% isopropyl alcohol
is the recommended but almost 20% of units (14/80, 18%) reported
using iodine preparations for skin decontamination and a further
third (27/80, 34%) reported the selection of skin preparation to be
surgeon dependent. Surgeon glove change prior to implant
handling was routinely performed (59/80, 74%) but mastectomy
pocket wash to remove debris was standard practice in just 60% ofunits (47/80) (Table 4). In linewith best practice guidelines, all units
reported the use of prophylactic antibiotics in IBBR but significant
variability was seen in both the type and duration of antibiotics
used. Broad-spectrum antibiotic prophylaxis with coverage of both
Gram-positive and Gram-negative organisms is recommended and
while most units reported using appropriate regimens either alone
(e.g co-amoxiclav) or in combination (e.g teicoplanin and genta-
micin), one in 10 units used narrower spectrum drugs such as
flucloxacillin only (6/60, 10%). Few units (8/60, 8% BM units and 2/
24, 8% SM units) adhered to the recommended single intravenous
dose at induction. Duration of antibiotic courses following both BM
and SM-assisted reconstruction were highly-variable ranging for
Table 4
Use of strategies to reduce risk of infection.
Strategy N ¼ 80 (%)
Routine pre-operative screening
MRSA
Yes 66 (83)
No 4 (5)
Missing 10 (13)
MSSA
Yes 25 (31)
No 45 (86)
Missing 10 (13)
Proportion of implant reconstruction cases performed in a laminar flow theatre
None 38 (48)
Approximately 25% 7 (9)
Approximately 50% 6 (8)
Approximately 75% 3 (4)
All cases 15 (19)
Missing 11 (14)
Type of skin preparation solution routinely used in patients having implant based reconstruction
Aqueous iodine 11 (14)
Alcoholic iodine 3 (4)
Chlorhexidine 19 (24)
2% chloraprep 10 (13)
Surgeon dependent 27 (34)
Missing 10 (13)
Use of cavity irrigation following mastectomy prior to implant insertion
Yes 47 (59)
No 5 (6)
Surgeon dependent 18 (23)
Missing 10 (13)
Surgeon glove change (or equivalent) prior to implant handling
Yes 59 (74)
No 3 (4)
Surgeon dependent 8 (10)
Missing 10 (13)
Antibiotic use for mesh based reconstruction
Biological mesh assisted implant reconstruction N ¼ 60
Antibiotic choice
Co-amoxiclav only 33
Flucloxacillin only 6
Flucloxacillin and gentamicin 5
Co-amoxiclav in combination with another antibiotic (e.g. gentamicin) 3
Teicoplanin and gentamicin 3
Cefuroxime 2
Flucloxacillin and ciprofloxacin 1
Flucloxacillin and teicoplanin 1
Teicoplanin only 1
Benzylpenecillin and flucloxacillin 1
Benzylpenecillin and gentamicin 1
Not specified 5
Antibiotic duration
One dose only 5
<24 h post-operative antibiotics 6
2 days 1
3 days 1
5 days 7
7 days 5
7e14 days 1
14 days 2
Until drains are out 25
Variable/surgeon dependant 4
Not stated 5
Synthetic mesh assisted implant reconstruction N ¼ 24
Antibiotic choice
Co-amoxiclav only 13
Flucloxacillin and gentamicin 2
Co-amoxiclav in combination with another antibiotic (e.g. gentamicin) 2
Teicoplanin and gentamicin 2
Teicoplanin only 1
Flucloxacillin/metronidazole/gentamicin 1
Surgeon dependant 1
Antibiotic duration
One dose only 2
Up to 24 h post-operative antibiotics (2e3 post operative doses) 4
2 days 1
(continued on next page)
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Table 4 (continued )
Strategy N ¼ 80 (%)
5 days 2
6 days 1
7 days 3
7e10 days 1
7e14 days 1
Until drains are out 7
Variable/surgeon dependant 1
Not stated 1
MRSA e methicillin resistant staphylococcus aureus; MSSA e methicillin sensitive staphylococcus aureus.
S. Mylvaganam et al. / European Journal of Surgical Oncology 44 (2018) 708e71671424 h to 14 days with oral antibiotics frequently continued until the
surgical drains were removed (BM 25/60, 40%; SM 7/24, 29%)
(Table 4).
Discussion
The iBRA national practice questionnaire suggests that adherence
to current best practice guidelines for IBBR in the UK is poor. Few
units reported obtaining clinical governance approval prior to of-
fering the new technique; having unit-specific protocols for the
management of patients undergoing mesh-assisted procedures or
specificwritten information for patients considering surgery. Despite
offering techniques with limited evidence for safety or effectiveness
and guidelines recommending robust prospective evaluation of
surgical outcomes, routine audit of cosmetic and patient reported
outcomes was infrequent. Clinical outcomes were more commonly
audited but this was often undertaken retrospectively. Procedure
coding was highly variable making future study of the procedure
through routinely available data sources such as Hospital Episode
Statistics (HES) difficult. Despite the significant impact of infection
and implant loss, adherence to current best-practice guidelines to
minimize these complications is inconsistent [6]. Strategies such as
MRSA screening; glove changes and peri-operative antibiotic usage
were standard practice in many units, but few units screened for
MSSA or had access to laminar flow for implant cases and antibiotic
choice and duration was variable. There is therefore a need for units
to consider implementing the best practice guidance and for high
quality research to establish best practice.
Guidelines aim to reduce variability and standardise practice to
improve outcomes for patients but despite these potential benefits
[19], compliance with clinical guidelines in many settings [20]
including breast [21] and plastic surgery [22] is known to be
poor. Reasons why guidelines are not implemented in practice for
this have been extensively investigated [20,23] and are likely to be
multifactorial. One element key to successful implementation, was
guideline validity and users' confidence that the guidelines were
evidence-based [23]. Evidence to support the practice of breast
reconstruction in general and IBBR in particular is lacking. This is
openly acknowledged in both the oncoplastic [6] and ADM [14]
guidelines and the lack of evidence to support proposed ‘best’
practice may partially explain why observed compliance with the
guidelines is poor. A recent review [24] evaluated the evidence for
infection prevention strategies in IBBR, many of which are currently
considered best practice. The review found evidence to support the
use of antibiotics; MRSA/MSSA screening; mastectomy pocket
irrigation and surgeon glove change in reducing the risk of infec-
tion, but suggested the evidence to support the use of laminar flow
and recommendation of specific skin preparation solutions in IBBR
to be less strong [24]. Evidence regarding the optimal duration of
antibiotics for infection prevention is also lacking. A recent single-
centre RCTof two-stage IBBRwith ADM compared infection rates in
patients receiving 24 h of antibiotic treatment vs. continuing an-
tibiotics until the surgical drains were removed [25]. This non-inferiority study which included 112 patients, demonstrated no
significant difference in infection rates between the treatment
groups (19.4% vs 22.0%). These results conflicted with earlier
observational studies which suggest significant benefits with
extended antibiotics in ADM-assisted reconstruction [26]. More
research is needed and well-designed multicentre prospective
studies and ideally RCTs are required to establish best practice.
This study has identified poor compliance with best practice
guidelines for IBBR in the UK but several factors require consider-
ation. This is a national practice survey and it is possible that the
reported practice differs from actual practice. As the survey sug-
gests poor compliancewith guidelines however, this is unlikely. It is
also possible that the survey responses reflected the practice of a
single surgeon rather than the unit as a whole. While this is
possible, a significant proportion of units reported ‘surgeon
dependent’ practice which suggested the views of the whole unit
were included. Overall response rate was relatively low with only
50% of breast units and 25% of plastic surgical units in the UK
completing the survey. This suggests that plastic surgical units were
relatively underrepresented but the poor response rate may reflect
the fact that the majority of IBBR in the UK is now performed by
breast rather than plastic surgeons. Plastic surgical units therefore
may not have perceived the study to be relevant to their practice.
Despite relatively low response rates the study population repre-
sents a geographically diverse sample that includes data from both
high and low volume centres and those with and without on-site
specialist plastic surgical services. This suggests that the results
reflect an accurate snap-shot of broad national practice.
While it may be justifiable that surgeons do not adhere to
guidelines that they do not perceive to be evidence-based or cannot
comply with recommendations due to lack of organizational
infrastructure (e.g access to theatres with laminar flow systems),
failure of units to comply with clinical governance recommenda-
tions such as obtaining appropriate local approvals prior to offering
a new technique; providing specific written information for pa-
tients considering surgery and failure to routinely audit the results
of the new technique is a previously unappreciated finding and
harder to defend. Adopting new techniques and devices into
practice without appropriate evaluation should not be acceptable
and in the wake of recent controversy surrounding the use of mesh
in gynaecological procedures [27], attention is increasingly focused
on the need for transparent and robust evaluation of novel in-
terventions, particularly if meshes are used. The IDEAL [28] (Idea,
Development, Exploration, Assessment and Long-term study)
framework provides a methodology by which this may be achieved
and the iBRA-NET initiative supported by the professional associ-
ations ABS and BAPRAS aims to promote the development and
delivery of IDEAL phase 2a/2b studies in reconstructive breast
surgery using a multicentre collaborative approach. Early phase
protocol-driven prospective studies and registries of new tech-
niques can provide early safety data, capture shared learning and
determine if and when an intervention is sufficiently stable for
formal evaluation, ideally in the context of a well-designed trial.
S. Mylvaganam et al. / European Journal of Surgical Oncology 44 (2018) 708e716 715The project is still in the development phase but breast and plastic
surgeons will need to work together and commit to the concept of
‘no innovation without evaluation’ if this approach is to become
standard practice.
There is a need for high quality evidence to inform best practice
in all areas of breast reconstruction but implant-based surgery is an
area where this is particularly lacking. The iBRA study [17], which
aims to inform the feasibility, design and conduct of a future trial in
IBBR may be the first important step in generating this evidence.
The prospective cohort stage of iBRA has recruited over 2000 pa-
tients from 70 centres across the UK and suggests that surgeons are
willing to evaluate when appropriate resources and infrastructure
are available. iBRA is the largest prospective study of new ap-
proaches to IBBR worldwide and so in addition to informing key
trial feasibility parameters such as outcome selection and sample
size, it is also anticipated that the dataset will provide a significant
resource for exploring best practice. This data will inform the
‘Getting it Right First Time’ (GIRFT) initiative in breast surgery
(http://gettingitrightfirsttime.co.uk/surgical-specialty/breast-
surgery/) which aims to improve the quality of care within the NHS
by reducing variation and disseminating best practice.
Conclusions
Compliance with breast practice guidelines for IBBR in the UK is
variable. Reasons for this are likely to be multifactorial but the lack
of high-quality evidence to support practice together with a lack of
infrastructure to meet recommendations may partially explain
these findings. Units' failure to comply with clinical governance
recommendations, in particular registration of new procedures and
prospective audit of outcomes was a previously unanticipated
finding and potentially a cause for concern. A development of
surgical culture with a commitment to a policy of ‘no innovation
without evaluation’ and a focus on undertaking high-quality
collaborative research is urgently needed to guide and support
best practice in breast reconstruction.
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